secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001213900-25-018135
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oramed's RoyaltyVest signs exclusive Rest of World license for Scilex lidocaine products ZTlido/SP-103
--------------------------------------------------------------------------------

- RoyaltyVest (50% owned by Oramed) obtains exclusive license to develop, manufacture and commercialize ZTlido (lidocaine 1.8%) and SP-103 outside the U.S.
- Revenue share: RoyaltyVest and Scilex Pharma each receive 50% of Net Revenue, paid quarterly by RoyaltyVest.
- Licensee must commit $200,000 annually (or in-kind) and obtain regulatory approval in at least one Major Market Country within 18 months of effective date.
- Scilex Holding Company guaranteed Scilex Pharma's obligations under the license via a parent guarantee; guarantee terminates upon a change of control.
- Oramed transferred 50% of RoyaltyVest shares to Oramed; Oramed controls half of RoyaltyVest's board of directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390025018135/0001213900-25-018135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390025018135/ea0232360-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-018135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer